[New Investment and Billing Listing Trends]

[New Investment and Billing Listing Trends]
*The result of the scale-up tips that I've been looking forward to came out at 3 a.m., so I went in and checked with someone in a good mood. First of all, the candidates for selection haha If you add this, it will add another difficult task like this year's preliminary unicorn and global expansion project. Of course, it's a preliminary unicorn > scale-up tips >> It's a global expansion, but the company is different

*The number of new investments was 31. Whatcha completed 36 billion Series D, which was received from July through multiclosing, 23.3 billion from Novelty Inc., 5 billion from Seromind Inc., 5 billion from Altos Ventures Inc., 4 billion from Meditip Inc., a licensed subsidiary of DreamCIS, and 4 billion from Brave Corp., which achieved annual sales of 10 billion won by selling chicken breasts through exercise creators.

*Bumbbit AI is a company co-represented by the CHO and CTO of Kakao Brain, and Altos Ventures invested 5 billion won as a seed. Netstream, which received SAFE investment from Korea Venture Investment, uses generative AI to create various solutions. Employees' education and management solutions are said to learn the current status of companies and match legal compulsory education, but I think it is an essential solution for a small company like us. I'm lazy to look for it and match it. lol

*The new claims included port X-ray technology company Seck, legendary cosmetics company Dalba Global, Cheongdam Global's cosmetics production subsidiary BioVizu, 3D printing company Link Solution, semiconductor ultrasound inspection equipment MIT, and OLED deposition process part company FineOne.

*As the end of the year approaches, there are a lot of companies that submit new approvals and reports. I'm a little embarrassed because there are many companies that schedule IR and submit reports as soon as the approval comes up to post it before the end of the year lol

*Winners, MotifLink, Samyang NCchem, Duchembio, and M&C Solutions were new approvals. Among them, companies that submitted reports included Duchembio and M&C Solutions.

*Of the five companies that submitted the report, there were only two PSRs and one EV/EBTIDA, so there were many companies that used relative valuation rather than PER. Oh, the companies that submitted the report include Day One Company, the former fast campus, Duchem Bio, a radioactive pharmaceutical subsidiary (54% stake) of Gio Young, Bodeok Unsaeng IGNet, a semiconductor equipment company IST, and M&C Solutions, which challenged KOSPI to be listed as a defense parts manufacturing industry.

*As a result of the public offering, SKEM and MOT recorded the bottom of the public offering band. In fact, I think it's almost the first time I've seen it, considering that a number of companies listed at the top are also showing a plunge of more than 30%, we can see how dead the sentiment is.

*Duchembio.. First of all, it is known to have a 90% market share for radioactive drugs. When I looked closely, I found out that it acquired Radio D&S Lab in August, 2004. Jio Young acquired the company in September, 2021, and the year-end sales were 10.9 billion won, which grows rapidly to 32.4 billion won in 22 and 34.6 billion won in 23 years. With 30 billion units of sales made and the listing this time, it offers a huge valuation of 16.48 times PSR by applying the cumulative sales in the third quarter of 24. While not applying the annual conversion sales, and applying the discount rate of 40%, I can't wait to see if he is trying to make a conservative claim.

*Day1 Company is also a company that proposed PSR. The company has few direct domestic peers, so it selects domestic and foreign comparative companies separately and applies different standards for the two markets, saying that it is due to the characteristics of the market. Unlike Duquem Bio above, PSR was applied by converting the sales in the second quarter of 24.
The method of selecting a comparative company is

Korea: 50% of sales within the education service industry are service sales, and there is no standard after listing (investment risk, suspension of transactions, accounting fraud, mergers and acquisitions, etc.)
Overseas: Companies excluding those with more than 100 billion in sales and less than 0.5 times PSR among educational service companies

It's been decided as.